MedTrace Logo

Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis

NCT03066609 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 543

Last updated 2019-12-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to determine if secukinumab is effective and safe in the treatment of plaque type psoriasis

Conditions

Interventions

DRUG

Secukinumab 150 mg s.c.

150 mg s.c. at randomization, Weeks 1, 2, 3, 4 and every 4 weeks till Week 48

DRUG

Secukinumab 300 mg s.c.

300 mg s.c. at randomization, Weeks 1, 2, 3, 4 and every 4 weeks till Week 48

DRUG

Placebo

Placebo 150 or 300 mg s.c at randomization, Weeks 1, 2, 3, 4, and 8. PASI responders at week 12 continued to receive placebo till Week 48. PASI non-responders at Week 12 received Secukinumab 300mg at Weeks 12, 13, 14, 15, 16 and every 4 weeks till Week 48

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-28
Primary Completion
2017-12-21
Completion
2018-11-20

Countries

  • China
  • Hungary
  • Malaysia
  • Philippines
  • Thailand
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03066609 on ClinicalTrials.gov